Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-09-07
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited, cell therapy, and RNA medicines for serious diseases, including CASGEVY with Vertex and several wholly owned clinical programs.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Platform proof now meets value-capture test
The upside case no longer rests on pure science. A rerating now requires one owned franchise, cleaner economics from the partnered launch, and evidence that platform breadth is real across more than one modality.

Analysis

Thesis
CRISPR Therapeutics has already cleared gene editing's first trust hurdle with CASGEVY; if it turns late-2026 to 2028 platform proof into one internally controlled franchise plus steadier CASGEVY economics, the stock can rerate from cash-backed optionality into a multi-franchise genetic medicines business.
Last Economy Alignment
AI makes discovery and design cheaper, but CRSP still owns the scarce pieces: biological IP, human data, regulatory trust, and some manufacturing. That is positive for more shots on goal, though not pivotal because biology, approvals, and partner-led commercialization still slow value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
The upside case is a change in market perception: from one approved but partner-controlled product to a company with one real owned franchise, a more legible CASGEVY profit stream, and at least one additional credible modality. That can support a solid rerating, but biology, manufacturing, and reimbursement complexity still cap the outcome below a clean hypergrowth scenario.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion, not cash. CRISPR must turn promising biology into durable, regulator-clean, reimbursable products while reducing dependence on Vertex for the only approved asset. If CTX310, CTX611, or zugo-cel fail to mature into commercially credible franchises, the stock can remain a partner-mediated platform story with slow direct revenue capture.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.32
They own hard-to-copy gene-editing know-how, human data, and some manufacturing, so cheaper AI discovery should give them more shots on goal. But biology, regulators, and a partner-controlled launch still slow how fast that science becomes shareholder value.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$87.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case